Acorda Therapeutics, Inc. (NASDAQ: ACOR) today announced President
and CEO Ron Cohen, M.D. has been appointed to the Executive Committee
of the Biotechnology Industry Organization (BIO). Dr. Cohen was also
named Vice Chair of the Emerging Companies Section of BIO. BIO is the
world’s largest biotechnology organization, providing advocacy,
business development and communications services for more than 1,200
members worldwide.
“BIO serves a critical role in promoting the discovery and
development of new technologies in various biotechnology fields,” said
Dr. Cohen. “It is a privilege to serve the organization in this new
capacity and I look forward to helping BIO fulfill its mission of
fostering scientific innovations that improve our healthcare,
agriculture and the environment. celexa. ”
Acorda has been a member of BIO since 1999, and Dr. Cohen has been
a member of the Emerging Companies Section since 2003. As Vice Chair,
he will help to design BIO’s agenda for serving the needs of small to
medium size BIO member companies, most of whom do not yet have major
products approved and on the market.
“Acorda’s growth from a small start-up to a fully-integrated
biotechnology company with multiple products in development
exemplifies how BIO members can mature and expand over time. BIO works
to maintain an environment for that kind of growth by advocating for a
favorable policy climate,” said James C. Greenwood, President and CEO
of BIO. “We are pleased to welcome Ron to the BIO leadership team, and
look forward to his continued contribution to our organization.”
About Acorda Therapeutics
Acorda Therapeutics is a biotechnology company developing
therapies for spinal cord injury, multiple sclerosis and related
nervous system disorders. The Company’s marketed products include
Zanaflex Capsules(R) (tizanidine hydrochloride), a short-acting drug
for the management of spasticity. Acorda’s lead clinical product,
Fampridine-SR, has completed two Phase 3 clinical trials to evaluate
its safety and efficacy to improve walking ability in people with MS.
The Company’s pipeline includes a number of products in development
for the treatment, regeneration and repair of the nervous system.
Acorda Therapeutics, Inc. Forward-Looking Statements
This press release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. All
statements, other than statements of historical facts, regarding
management’s expectations, beliefs, goals, plans or prospects should
be considered forward-looking. These statements are subject to risks
and uncertainties that could cause actual results to differ
materially, including delays in obtaining or failure to obtain FDA
approval of Fampridine-SR, the risk of unfavorable results from future
studies of Fampridine-SR, Acorda Therapeutics’ ability to successfully
market and sell Zanaflex Capsules(R), competition, failure to protect
its intellectual property or to defend against the intellectual
property claims of others, the ability to obtain additional financing
to support Acorda Therapeutics’ operations, and unfavorable results
from its preclinical programs. These and other risks are described in
greater detail in Acorda Therapeutics’ filings with the Securities and
Exchange Commission. Acorda Therapeutics may not actually achieve the
goals or plans described in its forward-looking statements, and
investors should not place undue reliance on these statements. Acorda
Therapeutics disclaims any intent or obligation to update any
forward-looking statements as a result of developments occurring after
the date of this press release.